<a href="https://www.fiercebiotech.com/biotech/immunovant-pays-out-39m-call-time-fcrn-inhibitor-after-eye-disease-fails" hreflang="en">Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails</a>
Immunovant has discontinued its FcRn inhibitor, batoclimab, after failing to meet primary endpoints in phase 3 trials for thyroid eye disease, resulting in a $39 million payout. Despite this setback, the company plans to leverage insights gained from the trials to inform the development of its second-generation FcRn blocker, IMVT-1402, which is currently undergoing various studies.
The discontinuation of Immunovant's first-generation FcRn inhibitor, batoclimab, due to failed phase 3 trials in thyroid eye disease highlights the critical need for robust early-stage trial design and adaptability in drug development strategies. However, the company's pivot to focus on its second-generation FcRn blocker, IMVT-1402, shows a strategic shift that could provide new opportunities, particularly with promising preliminary data in rheumatoid arthritis. Monitoring the upcoming trial results for IMVT-1402 could offer valuable insights and investment opportunities, especially given Immunovant's strong cash position and potential commercial launch prospects.